{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:12:49Z","timestamp":1788372769991,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antibody-drug conjugates (ADCs) have revolutionized oncology by integrating the target specificity of monoclonal antibodies with the potency of cytotoxic payloads. However, despite a subset of clinical trials and case reports documenting cutaneous adverse events (CAEs) associated with these agents, comprehensive systematic characterization of ADC-related CAEs remains elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data extracted from the FDA Adverse Event Reporting System (FAERS) spanning Q1 2004 to Q2 2025 included patient baseline characteristics. Disproportionality analyses\u2014reporting odds ratio (ROR) and information component (IC)\u2014were employed to identify safety signals, along with supplementary assessments of time-to-onset (TTO), clinical outcomes, and age- and gender-stratified risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,631 CAEs were identified. Concomitantly, a set of 31 positive signals (PT) was detected at the preferred term level, encompassing common manifestations such as rash, alopecia, bullous dermatitis, generalized exfoliative dermatitis, onycholysis, spider naevus, as well as rare but severe events with robust signals including Stevens-Johnson syndrome (SJS)-toxic epidermal necrolysis (TEN) overlap and generalized exfoliative dermatitis. Notably, positive PTs exhibited marked drug specificity: enfortumab vedotin was associated with the highest number of positive signals, whereas belantamab mafodotin displayed minimal signals. The median TTO of CAEs was 15 days, with trastuzumab deruxtecan demonstrating the shortest latency. Regarding clinical outcomes, hospitalization (23.4%) and death (7.7%) were prominent. Stratified analyses further revealed that elderly patients and males were more susceptible to ADC-related CAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings highlight significant risks of CAEs linked to ADCs, emphasizing the need for risk-stratified monitoring and personalized management. Furthermore, we identified some safety signals of CAEs that are not currently annotated in drug labeling, which provide critical real-world evidence to supplement and extend the limited clinical trial safety data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1847032","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:36:39Z","timestamp":1779683799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study"],"prefix":"10.3389","volume":"13","author":[{"given":"Huiwen","family":"Sun","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhan","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Yu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijin","family":"Shu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies.","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA: Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","article-title":"Antibody drug conjugates: lessons from 20 years of clinical experience.","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann Oncol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug conjugates: a comprehensive review.","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res MCR."},{"key":"B4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric Cancer.","volume":"393","author":"Shitara","year":"2025","journal-title":"New Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative Breast Cancer.","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"New Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates.","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discovery."},{"key":"B7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials.","volume":"18","author":"Tan","year":"2025","journal-title":"J Hematol Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","article-title":"Dermatologic toxicities of antibody-drug conjugates.","volume":"91","author":"Gronbeck","year":"2024","journal-title":"J Am Acad Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"384","author":"Powles","year":"2021","journal-title":"New Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"105082","DOI":"10.1016\/j.esmoop.2025.105082","article-title":"Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.","volume":"10","author":"Hu","year":"2025","journal-title":"ESMO Open."},{"key":"B13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours.","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev. Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/pharmaceutics15041132","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates administered via subcutaneous and intratumoral routes.","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Intern J Med Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1658535","DOI":"10.3389\/fimmu.2025.1658535","article-title":"Signal mining and analysis of influencing factors for adverse events of Nivolumab and Cetuximab in the treatment of head and neck cancer based on the US FAERS database.","volume":"16","author":"Tang","year":"2025","journal-title":"Front Immunol."},{"key":"B19","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [Guideline].","year":"2026"},{"key":"B20","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer [Guideline].","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/jco.24.00025","article-title":"Avoiding delays in reporting time-to-event randomized trials: calendar backstops and other approaches.","volume":"42","author":"Othus","year":"2024","journal-title":"J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1647944","DOI":"10.3389\/fimmu.2025.1647944","article-title":"Infectious adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FAERS database.","volume":"16","author":"Song","year":"2025","journal-title":"Front Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions.","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discovery."},{"key":"B24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths.","volume":"10","author":"Xu","year":"2023","journal-title":"Sci Data."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval.","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs."},{"key":"B26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/dddt.S240854","article-title":"Profile of enfortumab vedotin in the treatment of urothelial carcinoma: the evidence to date.","volume":"15","author":"Moussa","year":"2021","journal-title":"Drug Design Dev Therapy."},{"key":"B27","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1160\/th03-05-0302","article-title":"Regulatory roles of androgens in cutaneous wound healing.","volume":"90","author":"Gilliver","year":"2003","journal-title":"Thrombosis Haemostasis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1172\/jci39335","article-title":"Monocyte\/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression.","volume":"119","author":"Lai","year":"2009","journal-title":"J Clin Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12032-025-03193-3","article-title":"Drug-induced cutaneous toxicities in solid tumor oncology: mechanisms, manifestations, and management.","volume":"43","author":"Skossyrskiy","year":"2025","journal-title":"Med Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1124\/dmd.114.058586","article-title":"Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates.","volume":"42","author":"Han","year":"2014","journal-title":"Drug Metab Dispos."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/jcm10061332","article-title":"Whole-Body pharmacokinetics and physiologically based pharmacokinetic Model for Monomethyl Auristatin E (MMAE).","volume":"10","author":"Chang","year":"2021","journal-title":"J Clin Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/s0009-9236(97)90166-1","article-title":"Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions.","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin Pharmacol Therapeut."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.16770","article-title":"Langerhans cells express human \u03b2-defensin 3: relevance for immunity during skin ageing.","volume":"179","author":"Pilkington","year":"2018","journal-title":"Br J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fphar.2019.00373","article-title":"The analysis of key factors related to ADCs structural design.","volume":"10","author":"Tang","year":"2019","journal-title":"Front Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development.","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol Therapeut."},{"key":"B36","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial Cancer.","volume":"390","author":"Powles","year":"2024","journal-title":"New Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial Cancer: a single-center experience and review of the literature.","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis.","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/jid.2014.119","article-title":"Nectin-4 mutations causing ectodermal dysplasia with syndactyly perturb the rac1 pathway and the kinetics of adherens junction formation.","volume":"134","author":"Fortugno","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jaad.2024.07.1463","article-title":"Antibody-drug conjugates: a review of cutaneous adverse effects.","volume":"91","author":"Saberi","year":"2024","journal-title":"J Am Acad Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamadermatol.2022.1389","article-title":"Blistering lesions associated with loncastuximab tesirine.","volume":"158","author":"Gociman","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e70128","DOI":"10.1002\/hon.70128","article-title":"Management of adverse reactions to loncastuximab in patients with relapsed or refractory diffuse large B-cell lymphoma.","volume":"43","author":"Epperla","year":"2025","journal-title":"Hematol Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jamadermatol.2020.0208","article-title":"Diffuse telangiectatic rash associated with novel antibody drug conjugate therapies.","volume":"156","author":"Sorensen","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.3390\/ijms25147580","article-title":"Loncastuximab tesirine in the treatment of relapsed or refractory diffuse large B-cell lymphoma.","volume":"25","author":"Ju\u00e1rez-Salcedo","year":"2024","journal-title":"Intern J Mol Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/annonc\/mdu533","article-title":"T-DM1-related telangiectasias: a potential role in secondary bleeding events.","volume":"26","author":"Sibaud","year":"2015","journal-title":"Ann Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/j.chest.2015.09.008","article-title":"Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report.","volume":"149","author":"Kwon","year":"2016","journal-title":"Chest."},{"key":"B48","volume-title":"BLENREP (belantamab mafodotin-blmf) for Injection, for Intravenous Use [Prescribing Information].","year":"2025"},{"key":"B49","volume-title":"FASENRA (benralizumab) Injection, for Subcutaneous Use [Prescribing Information].","year":"2017"},{"key":"B50","volume-title":"TAKHZYRO (lanadelumab-flyo) injection, for Subcutaneous Use [Prescribing Information].","year":"2020"},{"key":"B51","volume-title":"POLIVY (polatuzumab vedotin-piiq) for Injection, for Intravenous Use [Prescribing Information].","year":"2019"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin.","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin.","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1111\/jdv.19454","article-title":"Skin toxicity of enfortumab vedotin: proposal of a specific management algorithm.","volume":"38","author":"Ingen-Housz-Oro","year":"2024","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"B55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/onco.13878","article-title":"Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities.","volume":"26","author":"Spring","year":"2021","journal-title":"Oncologist."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1847032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:15:43Z","timestamp":1788369343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1847032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":55,"alternative-id":["10.3389\/fmed.2026.1847032"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1847032","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1847032"}}